FGFR
10 drugsFibroblast Growth Factor Receptor
Predictive biomarker for patient selection in 26 indications
Understanding FGFR
What it means: FGFR alterations include fusions, amplifications, and mutations across FGFR1-4. Common in bladder, breast, and cholangiocarcinoma.
Why it matters: FGFR inhibitors (erdafitinib, pemigatinib, futibatinib) target FGFR-altered cancers with good response rates.
Testing: Tested via NGS to identify fusions, mutations, and amplifications across FGFR1-4 genes.
10
Approved Drugs
26
Indications
10
Companies
Search FGFR Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting FGFR
| Drug | Company | Therapeutic Area |
|---|---|---|
| BALVERSA | Johnson & Johnson | Oncology |
| GAVRETO | RIGEL PHARMS | Oncology |
| ICLUSIG | Takeda | Oncology |
| LENVIMA | EISAI INC | Oncology |
| OFEV | Boehringer Ingelheim | Respiratory |
| PAZOPANIB HYDROCHLORIDE | Teva | Oncology |
| PEMAZYRE | INCYTE CORP | Oncology |
| RETEVMO | Eli Lilly | Oncology |
| STIVARGA | Bayer | Oncology |
| VOTRIENT | Novartis | Oncology |
Indications
Metastatic colorectal cancer Locally advanced, unresectable or metastatic gastrointestinal stromal tumor Hepatocellular carcinoma Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer Advanced renal cell carcinoma (first-line, in combination with pembrolizumab) Advanced renal cell carcinoma following one prior anti-angiogenic therapy (in combination with everolimus) Unresectable hepatocellular carcinoma (first-line) Advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) following prior systemic therapy (in combination with pembrolizumab) Cholangiocarcinoma Myeloid/Lymphoid Neoplasms Metastatic RET fusion-positive non-small cell lung cancer Advanced or metastatic RET fusion-positive thyroid cancer Renal Cell Carcinoma Soft Tissue Sarcoma Non-Small Cell Lung Cancer Medullary Thyroid Cancer Thyroid Cancer Solid Tumors Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Systemic Sclerosis-Associated Interstitial Lung Disease Urothelial Carcinoma Advanced renal cell carcinoma Advanced soft tissue sarcoma Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia